Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

Item

http://www.wikidata.org/entity/Q33846178

Q33846178

about

Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice Colony-stimulating factors for febrile neutropenia during cancer therapy.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin.Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma.High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer."Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe.

P2860

Q27004054-C18B298A-8BE7-461C-949E-B97F56D921D8 Q29994513-9878F2AD-3C52-4E97-ADA3-EBEE4492CC3C Q36723903-37A63711-BE98-4547-B28F-9AB27CF0F384 Q36762853-DAF3E390-33BF-43B9-8BDC-107691D56092 Q37554901-C77909BD-09DE-41DC-9680-9EAC9FF87375 Q37626772-B0E5EEB2-1A7D-4CE0-B778-CABBEE55B218 Q38072290-91C814C5-9B21-44AB-AB7B-7614DC1EEA98 Q38256944-225D9F8A-CBDF-4552-A868-B918E3B84CAE Q38608267-95560CE3-BEE7-47FC-BCD6-561DEDF312CF Q39297322-C2239F3A-9DAA-4325-80B2-2C3A0808B1FC Q40074708-FBDE8FB9-CF0E-4336-8E78-E44CF427583C Q40147851-834E2C5B-49E5-4347-9E07-7E4EB3EE5474 Q40307046-55DC38FE-DAE7-4719-8B43-9338572F684F Q41142382-942E3A1A-F680-48C3-9522-EA3C7F1D7ECD Q41441391-346C80CB-5016-4D94-A881-40D3E884C467 Q41453238-6A2FE4D1-2332-471C-BF7B-EC9D1379F016 Q41958401-EDA6AE92-4B07-4AB0-BB09-EE11AC516FCE Q47668200-FF00AE29-8B0E-4BBA-8904-C16FD82EE4DD Q50001689-978EAD48-6716-4910-95C1-71C3416E28F4 Q53161630-A7D75D87-08D8-4A3C-A192-B440435A590A Q53534502-F57A1BBC-4343-4D4A-AF49-2117FA0A06FA

P2860

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

Item

http://www.wikidata.org/entity/Q33846178

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu